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ClC proteins are a family of chloride 
channels and transporters that are found in a 
wide variety of prokaryotic and eukaryotic cell-
types. The mammalian voltage-gated chloride 
channel ClC-1 is important for controlling the 
electrical excitability of skeletal muscle. 
Reduced excitability of muscle cells during 
metabolic stress can protect cells from 
metabolic exhaustion and is thought to be a 
major factor in fatigue. Here we identify a novel 
mechanism linking excitability to metabolic 
state by showing that ClC-1 channels are 
modulated by ATP. The high concentration of 
ATP in resting muscle effectively inhibits ClC-1 
activity by shifting the voltage-gating to more 
positive potentials. ADP and AMP had similar 
effects to ATP but IMP had no effect, indicating 
that the inhibition of ClC-1 would only be 
relieved under anaerobic conditions such as 
intense muscle activity or ischaemia, when 
depleted ATP accumulates as IMP. The 
resulting increase in ClC-1 activity under these 
conditions would reduce muscle excitability, 
thus contributing to fatigue. We show further 
that the modulation by ATP is mediated by 
cystathionine-β-synthase-related (CBS) 
domains in the cytoplasmic C-terminus of ClC-
1. This defines a function for these domains as 
gating-modulatory domains sensitive to 
intracellular ligands, such as nucleotides, a 
function that is likely to be conserved in other 
ClC proteins.  
Skeletal muscle has a high and variable 
demand for energy, in the form of ATP, and has 
elaborate systems to maintain the ATP supply. 
During intense exercise, however, ATP supply 
may not keep up with demand and ATP 
concentration can decrease rapidly. In fast-twitch 
fibres ATP can drop to below 25% of resting 
concentration within 25 seconds (1), a rate of ATP 
consumption that, if it continued, would deplete all 
ATP within a further 10 seconds. As the majority 
of ATP is consumed by the sarcoplasmic reticulum 
(SR)1 Ca2+-ATPase pumping Ca2+ back into the SR 
after each Ca2+-activated contraction (2), complete 
ATP depletion would lead to a rise in cytoplasmic 
calcium, rigor and calcium-dependent damage 
(3,4). This does not normally occur because force 
generation and ATP consumption decrease during 
exercise, compromising short-term function but 
protecting cells from complete metabolic 
exhaustion. This process is well known as fatigue 
but the factors contributing to fatigue remain 
controversial. Direct reduction in force generation 
by the contractile apparatus is thought to be a 
factor early in fatigue (3,5) but a significant 
reduction in ATP consumption only occurs with a 
reduction in SR Ca2+ release (and consequent 
reuptake) that occurs late in fatigue, correlating 
with ATP depletion (3). Indeed, ATP depletion 
and the concomitant increase in cytoplasmic Mg2+ 
directly reduce the activity of the SR Ca2+ release 
channel and may contribute to fatigue (6). A 
reduction in the electrical excitation that stimulates 
SR Ca2+ release is also thought be a major 
contributor to fatigue (7). 
Activation, or excitation, of skeletal 
muscle is initiated at the neuromuscular junction 
by nicotinic acetylcholine receptor-mediated 
postsynaptic Na+ currents, leading to membrane 
depolarization. These currents are large so the 
threshold potential for voltage-gated Na+ channels 
is reached with high probability, leading to action 
potential initiation. Membrane repolarization 
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following an action potential is mediated by 
voltage-gated K+ channels and the voltage-gated 
Cl- channel, ClC-1 (8), both of which are activated 
by membrane depolarization. A significant 
proportion of ClC-1 channels remain open in 
resting muscle, acting as a barrier to depolarization 
that must be overcome for successful action 
potential generation. Action potentials are 
propagated along the surface membrane and into 
the internal network of membrane tubes (T-
tubules) where they activate voltage sensors in the 
dihydropyridine receptor, stimulating Ca2+ release 
from the SR and muscle contraction. During 
intense exercise, run-down of Na+ and K+ gradients 
in the restricted volume of the T-tubules is thought 
to reduce action potential propagation and 
contribute to fatigue (7). ATP-sensitive K+ (KATP)1 
channels (9) provide a mechanism for linking 
excitability to metabolic state but, although KATP 
channels reduce excitability and protect cardiac 
muscle cells during ischemia (10), they do not 
appear to contribute significantly to force 
reduction during fatigue in skeletal muscle (11). 
ClC-1 channels are important regulators of 
skeletal-muscle excitability, as highlighted by 
muscle hyper-excitability due to mutations in ClC-
1 in congenital myotonia (12) and aberrant splicing 
of ClC-1 in myotonic dystrophy (13,14). To date 
there is no evidence, however, that ClC-1 
differentially regulates excitability during 
metabolic stress. 
Like other ClC family members, the ClC-1 
protein comprises a large membrane-embedded 
channel domain followed by two cytoplasmic 
cystathionine β-synthase related (CBS)1 domains 
(15) (Fig. 1) and is thought to form homodimers 
with an ion conducting pore within each monomer, 
as revealed by the structure of a bacterial ClC (16). 
Voltage-dependent gating of ClC-1 has two 
components that are both activated by 
depolarization, fast or protopore gating that occurs 
independently in each pore and slow or common 
gating that operates on both pores simultaneously 
(17). Little is known about the mechanism of 
common gating but its temperature dependence 
(18,19) indicates that it involves substantial 
conformational changes. Perhaps not surprisingly, 
mutations of ClC-1 that lead to dominantly 
inherited myotonia (Thomsen’s disease) tend to 
affect the voltage dependence of common gating 
and cluster at the dimer interface (12). More 
surprisingly, modifications of the cytoplasmic CBS 
domains also affect common gating, or in some 
cases abrogate channel function (20-22). Although 
the functional role of CBS domains in ClC proteins 
remains unclear their importance to channel 
function is underlined by disease causing 
mutations. In humans mutations in the CBS 
domains of ClC-1 underlie congenital myotonia 
(23), in ClC-2 generalized idiopathic epilepsy (24), 
in ClC-5 hypercalciuric nephrolithiasis (25), in 
ClC-Kb Bartter syndrome (26) and in ClC-7 
infantile malignant osteopetrosis (27). 
In the present work we show that ATP 
modulates common gating of ClC-1, a mechanism 
that is likely to reduce the excitability of skeletal 
muscle and contribute to fatigue during severe 
metabolic stress. Furthermore, we show that the 
regulatory effect of ATP on channel-gating is 
mediated by the CBS domains of ClC-1, defining a 
functional role for these domains. 
 
 
MATERIALS AND METHODS 
 
Channel expression and site-directed mutagenesis 
- Human ClCN1 was expressed using a pCIneo 
(Promega) mammalian expression vector, as 
detailed previously (19,28).  Human embryonic 
kidney (HEK293T)1 cells (American Type Culture 
Collection, Rockville, MD, USA) were transiently 
transfected with a mixture of the ClCN1 construct 
and pEGFP-N1 (Clontech) reporter plasmid at a 
molar ratio of 3:1 using Effectene (Qiagen), 
according to the manufacturer's specifications.  
Transfected cells were later identified by 
reporter-plasmid driven expression of the green 
fluorescent protein. Mutations were introduced 
into ClCN1 using the Quickchange (Stratagene) 
mutagenesis technique. The mutagenic primers 
were designed to incorporate silent restriction sites 
to aid in the identification of successfully mutated 
plasmid DNA. Mutant clones that were identified 
using restriction analysis were subsequently 
verified by sequencing.  
 
Electrophysiology - Patch-clamp experiments were 
conducted at room temperature (23 ± 1 °C) in the 
whole-cell configuration using an Axopatch 200B 
patch-clamp amplifier (Axon Instruments, Foster 
City, CA, USA) and associated standard 
equipment. Cells were continuously superfused 
with bath solution containing (mM): NaCl, 140; 
CsCl, 4; CaCl2, 2; MgCl2, 2; Hepes, 10; adjusted to 
pH 7.4 with NaOH. The standard pipette solution 
contained (mM): CsCl, 40; Caesium glutamate, 80; 
EGTA-Na, 10; Hepes, 10; adjusted to pH 7.2 with 
NaOH. Stock solutions of the following nucleotide 
salts: ATP di-sodium, ATP magnesium, ADP di-
sodium, AMP di-sodium, IMP di-sodium, GTP 
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lithium and adenosine-3’,5’-cyclic-monophosphate 
(cAMP) 2-amino-2-(hydroxymethyl)-1,3-
propanediol (Tris) were stored at –20°C and 
diluted in pipette solution on the day of each 
experiment. Solutions of 5 mM adenine and 
adenosine in pipette solution were made fresh on 
the day they were used. Patch pipettes were pulled 
from borosilicate glass, and typically had 
resistance of 1-2 MΩ when filled with the above 
pipette solution.  Series resistance did not exceed 4 
MΩ and was 85-95 % compensated. After 
rupturing the cell membrane and achieving the 
whole-cell configuration, no less than 5 minutes 
was allowed for the pipette solution to equilibrate 
with the intracellular solution before current 
recordings were made. Currents obtained at a 
sampling frequency of 10 kHz were filtered at 5 
kHz, and collected using Axograph (Axon 
Instruments, Foster City, CA, USA) software. 
 
Data analysis - Data were analyzed using 
Axograph 4.9 (Axon Instruments, Foster City, CA, 
USA) and GraphPad Prism 4.0 (GraphPad 
software, San Diego, CA, USA) software. The 
voltage dependence of channel inactivation was 
determined by measuring tail-current relaxation at 
a constant voltage of –100 mV for a period of 75 
ms, after a test pulse at voltages ranging from –140 
to +120 mV. Under certain conditions (for 
example in the presence of intracellular ATP), and 
for certain mutations current activation at positive 
potentials was slowed. For this reason the time of 
the test pulse was varied between 300 and 800 ms, 
depending on the degree of channel activation; a 
manipulation that in itself has previously been 
shown to have little effect on the determination of 
channel open probability (29). Between test 
sweeps the cell membrane was clamped at a 
holding potential of –30 mV for a period of 2 s. 
Current relaxations during the –100 mV tail pulse 
were fit with an equation of the form  
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where I is the whole-cell current, t is time, τ1 and 
τ2 are the time constants of the fast and slow 
components of current relaxation, respectively, and 
A1, A2 and C are the amplitudes of the fast, slow 
and steady-state components of the current, 
respectively. Instantaneous current amplitudes at 
the start of the –100 mV pulse (I(0)) were 
determined by extrapolation of this function. To 
obtain the voltage dependence of the apparent 
channel open-probability (Po), normalised 
instantaneous current amplitudes were fit with a 
modified Boltzmann distribution of the form 
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where Pmin is an offset, or a minimal open 
probability at very negative potentials, V is the 
membrane potential, V1/2 is the half-maximal 
activation potential, and k is the slope factor. To 
determine the voltage dependence of the slow or 
common gate that acts simultaneously on both 
protopores of a ClC-1 dimer, a 400 µs pulse to 
+170mV was inserted before the –100 mV tail 
pulse, to maximally activate the fast or protopore 
gate. Instantaneous tail-current amplitudes, 
determined as described above were fit with 
equation (2) to yield Po(V) for the common gate. 
Open probability of the protopore gate was 
determined by dividing the apparent channel open 
probability by the open probability of the common 
gate. This data was fit with equation (2) to yield 
Po(V) curves for the protopore gate. All data are 
expressed as means ± SEM. 
 
Homology modelling and nucleotide docking - The 
CBS domains from ClC-1 were individually 
modelled on the crystal structure of IMPDH from 
Streptococcus pyogenes (PDB entry 1ZFJ) using 
COMPOSER, a component of Sybyl 6.92 (Tripos 
Inc.). The individual domain models were then 
assembled with reference to the atomic coordinates 
of the IMPDH CBS dimer to form CBS 1/2 dimers 
in SwissPDB viewer (30), followed by energy 
minimisation using Sybyl6.92. Two alternative 
models were built based on different alignments in 
one strand of CBS 2. The quality of both models 
was assessed, and found to be satisfactory using 
Verify3D (31). The model with the best Verify3D 
score was chosen as the preferred model for in 
silico docking studies, and is presented here. 
AutoDock 3.0 (32) was used to explore the 
interaction of AMP and ATP with the entire 
surface of this ClC-1 CBS model. The Lamarckian 
genetic algorithm was used to produce 100 
conformations of each ligand, which were 
clustered within a root mean square deviation of 
1.8 Å. Docked conformations of the ligands were 
inspected using VMD version 1.8 (33). 
  
 
RESULTS 
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Intracellular ATP regulates ClC-1 common gating 
- During whole-cell patch clamp measurements of 
heterologously expressed ClC-1 channels, we 
observed that the voltage dependence of ClC-1 
gating shifts to more negative potentials over the 
first few minutes after rupturing the cell 
membrane, indicating that ClC-1 gating might be 
modulated by a diffusible factor present in the 
cytoplasm that is diluted upon membrane rupture. 
Given the high ATP turnover of active skeletal 
muscle, we postulated that this factor might be 
ATP or one of its metabolites, perhaps linking 
excitability to metabolic state via regulation of 
ClC-1 channels in a similar manner to regulation 
of KATP channels (9,34). We found that ATP did 
indeed have a marked effect on the voltage 
dependence of ClC-1 gating, predominantly 
affecting common gating with little effect on 
protopore gating (Fig. 2). Inclusion of 5 mM ATP, 
similar to the concentration in resting muscle, in 
the intracellular solution during whole-cell patch 
clamp recordings altered common gating such that 
the midpoint of the voltage sensitivity curve (V1/2) 
shifted to less negative potentials by approximately 
50 mV and the fraction of channels that remained 
open at strongly negative potentials (Pmin) was 
reduced approximately 6-fold (Fig. 2). The non-
hydrolysable ATP analogue, ATP-γs had a similar 
effect to ATP on common gating, indicating that 
this effect does not involve ATP hydrolysis and is 
likely to be due simply to ATP binding. Although 
ATP is often complexed with Mg2+, equimolar 
Mg2+ did not influence the effect of ATP on 
common gating. The effect of ATP on the voltage-
dependence of ClC-1 common gating was 
concentration dependent, with a half-saturation 
concentration of approximately 1 mM (Fig. 2B), 
similar to the concentration reached in fast-twitch 
fibres after 25 seconds of intense exercise (1). 
During moderate exercise, although ATP turnover 
increases markedly, a variety of systems maintain 
ATP at close to resting levels of 5-7 mM, 
minimizing any effect on ClC-1 voltage 
sensitivity.  
Slight ATP depletion during exercise does, 
however, show up as proportionally larger 
increases in its metabolites adenosine 5’-
diphosphate (ADP) and particularly adenosine 5’-
monophosphate (AMP). Differential regulation by 
these metabolites could be a factor in ClC-1 
regulation as it is in other systems (34). We found, 
however, that AMP had a similar effect to ATP on 
ClC-1 common gating (Fig. 2), as did ADP. 
Furthermore 1 µM AMP, a high level 
physiologically, had no influence on the effect of 5 
mM ATP on common gating, indicating that the 
ClC-1 common gating is not sensitive to the 
AMP:ATP ratio. We also investigated the effect on 
ClC-1 common gating of the metabolic breakdown 
products of AMP, adenosine and adenine. The 
effect of adenosine on common gating was similar 
to that of ATP or AMP, at both 5 mM and 1 mM 
(Fig. 2D). These results demonstrate that the 
presence of phosphates attached to adenosine are 
not important for the effect on common gating and 
reiterate that hydrolysis of a nucleotide high-
energy phosphate bond is not necessary for this 
effect. The effect on common gating of 5 mM 
adenine was much less than that of adenosine, 
ATP or AMP (Fig. 2D), indicating that the ribose 
ring of adenosine is important for this effect. 
Although these data are useful in understanding 
ligand specificity, they do not indicate a 
physiological role for adenosine and adenine in 
regulating ClC-1 as the concentrations in skeletal 
muscle are well below the mM levels used here. 
Furthermore, their concentrations do not increase 
greatly during metabolic stress, due to the very 
high AMP deaminase activity that directs AMP 
breakdown to IMP rather than adenosine (35,36). 
Taken together, these data indicate that although 
ClC-1 common gating is clearly modulated by 
adenosine nucleotides it is unlikely to be affected 
by the small changes that occur in the 
concentration of these nucleotides during moderate 
exercise. 
Under the anaerobic conditions of severe 
metabolic stress such as intense sprint exercise or 
ischemia, however, ATP can be depleted to less 
than 1 mM (1,35), accumulating as inosine 5’-
monophosphate (IMP), the product of AMP 
deamination (37,38). We found that 5 mM 
intracellular IMP had no effect on ClC-1 common 
gating (Fig. 2A). Furthermore the effect of a 
mixture of 2.5 mM IMP and 2.5 mM ATP on 
common gating was essentially indistinguishable 
from 2.5 mM ATP alone. These data indicate that 
under conditions of severe metabolic stress when 
ATP is broken down to IMP, the drop in ATP 
concentration would lead to a shift in the voltage 
dependence of ClC-1 common gating towards 
more negative potentials. 
We also investigated the potential role of 
other nucleotides. As for IMP, inclusion of 5 mM 
guanosine 5’-triphosphate (GTP) in the 
intracellular solution did not affect the voltage 
dependence of ClC-1 common gating (Fig. 2A), 
indicating some specificity for adenosine 
nucleotides. Inclusion of 5 mM adenosine 3’, 5’-
cyclic monophosphate (cAMP) in the intracellular 
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solution reduced Pmin slightly, similar to sub-mM 
AMP, suggesting that AMP cyclisation reduces 
binding affinity (Fig. 2A). 
 
ATP modulation is mediated by CBS domains of 
ClC-1 - Having shown that intracellular ATP 
regulates ClC-1 activity, we then investigated 
whether this might occur by direct binding to the 
intracellular side of ClC-1. Tandem CBS domains 
in the carboxy-terminus of ClC-1 (15,39), seemed 
to be the best candidates for a potential ATP-
binding site as they are the only defined 
cytoplasmic domains, modification of them affects 
common gating (20-22) and CBS domains occur in  
a number of nucleotide-sensitive proteins. 
Consistent with this postulate, Scott and colleagues 
(40) have shown recently that CBS domains of 
AMP-activated protein kinase and IMP 
dehydrogenas-1 bind nucleotides and regulate 
enzyme activity and that a piece ot the C-terminal 
tail of ClC-2, including the two CBS domains, is 
able to bind ATP. To examine the possibility that 
CBS domains of ClC-1 might bind ATP we built 
homology models based on the structure of a CBS 
dimer from bacterial inosine monophosphate 
dehydrogenase (IMPDH) (41) (Fig. 3). The 
validity of this structure as a modelling template is 
supported by the observation that CBS domains 
from mammalian IMPDH can substitute for those 
of ClC-1 while retaining channel function (21). In 
silico docking of AMP and ATP to this model 
identified a putative binding pocket between CBS 
1 and 2 (Fig. 3B) lined by residues T636, P638 and 
S651 from CBS 1 and H847, L848 and V860 from 
CBS 2. The adenine base is predicted to bind deep 
within this pocket, close to L848, with the ribose 
ring at the top of the pocket, close to T636 and 
H847.  
Mutagenesis of individual residues lining 
the putative ATP-binding site reduced (T636A, 
P638A or H847A) or abrogated (L848A) the effect 
of ATP on the voltage dependence of common 
gating (Fig. 4, Table 1), supporting both our model 
of an ATP-binding site at the CBS domain dimer 
interface and the hypothesis that this site mediates 
ATP regulation of ClC-1 common gating. 
Mutations of other residues, A849 that faces away 
from the putative binding pocket and S651 that 
faces into the putative binding pocket but is not 
predicted to interact directly with bound ATP, had 
little effect on ATP sensitivity (Fig. 4, Table 1), 
consistent with the details of our model. The fact 
that functional ClC-1 channels were observed for 
all of these mutants indicates a specific effect on 
ATP modulation rather than non-specific 
disruption of the CBS domain structure, as such 
disruption also appears to disrupt channel function 
(21). We also tested the effect of a myotonia 
associated mutation, G859D (12,23), in CBS 2 but 
functional ClC-1 channels were not observed, 
presumably due to disruption of the CBS domain 
structure. Interestingly, all of the mutations that 
reduced the effect of ATP also shifted the voltage-
dependence of common gating in the absence of 
nucleotide to be more like that of wt ClC-1 in the 
presence of ATP (Fig. 4).  
 
 
DISCUSSION 
 
We have demonstrated here a novel 
regulation of ClC-1 voltage sensitivity by 
intracellular adenosine nucleotides that would 
result in significant inhibition of ClC-1 activity by 
the high ATP concentration in resting and 
moderately exercising muscle. This inhibition is 
only likely to be alleviated during anaerobic 
conditions such as intense exercise or ischemia 
when marked ATP depletion occurs, accumulating 
as IMP (1). The physiological significance of ATP 
regulation of ClC-1 remains to be elucidated but 
the obvious prediction from our results is that, 
similar to KATP channels in cardiac muscle (10), 
increased ClC-1 activity due to ATP depletion 
during metabolic stress would stabilize the 
membrane potential and reduce skeletal muscle 
excitability. Given the significantly increased ClC-
1 activity at resting membrane potentials in the 
absence of ATP, excitability could be reduced by 
preventing initiation of action potentials as well as 
reducing their amplitude and time-course. Reduced 
excitability would protect cells both from the toxic 
effects of prolonged depolarization and, by 
reducing ATP demand, from complete ATP 
depletion and Ca2+-dependent damage. At the same 
time this reduced excitability is likely to contribute 
to fatigue. This mechanism may be most 
significant during intense sprint-type exercise in 
fast-twitch muscle fibres where ATP depletion is 
greatest (1) and expression of ClC-1 is also 
greatest (42). ClC-1 appears to be present 
primarily in the surface membrane of muscle fibres 
and is more densely clustered around the 
neuromuscular junction (42,43), a location where it 
will have the greatest effect on action potential 
initiation and propagation. ATP modulation of 
ClC-1 channels is one of many regulatory 
mechanisms that are likely to contribute to fatigue 
but, as with metabolic pathways, modulation of 
such an early step in the excitation-contraction 
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pathway of skeletal muscle may be the most 
effective and efficient means of regulating ATP 
consumption. 
Muscle acidosis, another consequence of 
anaerobic conditions that has long been thought to 
contribute to fatigue, has also been reported to 
increase ClC-1 activity (44) so could contribute to 
fatigue by reducing muscle excitability using the 
same argument as we have outlined above. This 
possibility and the general concept that acidosis 
contributes to fatigue are contradicted, however, 
by observations that acidosis preserves the 
excitability of depolarized muscle fibres and T-
tubule membranes by decreasing the Cl- 
conductance of the muscle sarcolemma (45-48). 
The relative contribution of acidosis and ATP 
depletion to fatigue and the extent to which ClC-1 
is involved clearly requires further investigation. 
Using molecular modeling and in silico 
docking, we have identified a putative ATP-
binding site in a cleft between the two C-terminal 
cytoplasmic CBS domains of ClC-1. We found 
that mutation of residues predicted to interact with 
ATP at this site, reduced or abrogated the effect of 
ATP on ClC-1 voltage dependence, whilst 
mutation of residues in the local area of the 
proposed binding site that were not predicted to be 
important for binding had little or no impact on 
ATP modulation. These results clearly demonstrate 
the role of the CBS domains in mediating the 
modulatory effect of ATP and support our model 
of the ATP-binding site (Fig. 3). Scott and 
colleagues (40) have shown recently that CBS 
domains act as nucleotide-binding regulatory 
domains in a number of enzymes. They also 
showed that when expressed as a GST-fusion, a 
piece of the C-terminal tail of ClC-2, including the 
two CBS domains, can bind ATP but the 
functional effect of this binding was not tested. 
The results we have presented here show for the 
first time that CBS domains of a ClC channel 
regulate channel activity in response to binding of 
an intracellular ligand, in this case ATP. We have 
shown further that this regulation occurs by 
shifting the voltage dependence of common gating. 
It has been shown that mutations within the CBS 
domains of ClC proteins affect common gating 
(12,21) but physiologically relevant regulatory 
roles for these domains have not been identified 
previously (21). We have now identified such a 
role for the CBS domains of ClC-1. 
It is not clear whether CBS domains have 
a similar role in other ClC proteins but there are a 
couple of reports in the literature of adenosine 
nucleotides affecting ClC channel activity. Firstly, 
Vanoye and George (49) showed that ATP was 
required for continued ClC-4 activity. A sizeable 
part of this effect was due to ATP hydrolysis 
suggesting a mechanism involving protein 
phosphorylation. It was unclear whether ATP 
affected ClC-4 gating, trafficking, or other factors. 
More recently, Niemeyer and colleagues (50) 
showed that replacement of intracellular ATP with 
AMP increased the rate of activation and 
deactivation for ClC-2. Whether this effect was 
due to ATP hydrolysis was not tested but the effect 
was reduced by an epilepsy-linked G715E 
mutation close to two defined protein kinase A 
phosphorylation sites, T655 and T691 (51), in a 
large loop between the two CBS domains. There is 
no direct evidence in either of the above cases that 
the effects of nucleotides on channel function 
involve the CBS domains or changes in the voltage 
dependence of gating. Thus it remains to be 
elucidated whether the underlying mechanism is 
related to the one we have described here for ClC-
1. 
As voltage can be sensed exclusively 
across the membrane, the involvement of the 
cytoplasmic CBS domains in the voltage-
dependence of ClC-1 common gating suggests 
intimate interactions between the CBS domains 
and the membrane inserted channel domain 
(21,52). ATP may exert its effect on common 
gating by allosterically modulating the interaction 
between the CBS and channel domains and hence 
gating within the channel domain itself.  A similar 
allosteric mechanism could explain the effect of 
CBS mutations that shifted common gating in the 
absence of nucleotide to be more like wt in the 
presence of ATP, as well as reducing the effect of 
ATP (Fig. 4). Alternatively, ATP could exert its 
effect by competitively disrupting an interaction 
between the CBS domains and cytoplasmic loops 
from the channel domain that act as alternate 
ligands for the ATP-binding site. In this model a 
mutation in the ATP-binding site could 
simultaneously disrupt binding of both ligands, 
mimicking the effect of ATP binding at the same 
time as eliminating the effect of ATP, consistent 
with the mutational effects we have observed. In 
support of this model, mutations on the surface of 
CBS2 (21), close to but not directly involved in the 
putative ATP-binding site, and in one of the 
cytoplasmic loops of the channel domain (53,54) 
shift the voltage-dependence of common gating to 
more positive values, perhaps also by disrupting 
interactions between the CBS and channel 
domains. The veracity of this hypothesis will only 
become clear when detailed structural information 
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showing interactions between channel and CBS 
domains becomes available.  
 Based on our results showing that the CBS 
domains of ClC-1 mediate ATP modulation of 
common gating, we propose that these domains 
can be thought of as channel regulatory domains 
sensitive to intracellular ligands, analogous to the 
variety of cytoplasmic regulatory domains 
associated with K+ channels (55). ClC proteins 
comprise a large family of Cl--selective ion 
channels and transporters (56) that are widespread 
in prokaryotic and eukaryotic cells and are 
involved in a diverse range of physiological 
functions (8)  but CBS domains are conserved in 
most ClC proteins (Fig. 1). We speculate that the 
function of these domains as channel regulators 
sensitive to intracellular ligands is also likely to be 
conserved and that whilst their ligand-sensitivity 
may vary, nucleotide sensitivity could be a 
recurring theme. The bacterial ClC homologues 
from Escherichia coli and Salmonella typhimurium 
for which high resolution structures have been 
solved lack CBS domains (16), but other 
prokaryotic ClC proteins have CBS domains (Fig. 
1), making them prime targets for structural 
studies. Curiously some prokaryotic ClC proteins 
have additional tandem USPA domains, which 
have also been implicated in ATP binding (Fig. 1) 
(57). 
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FIG. LEGENDS 
 
Fig. 1. Structural conservation in the ClC family. Schematic diagram illustrating domain organization 
of various ClC proteins, drawn to scale shown at bottom right of figure. Shown are the human isoforms of 
the mammalian ClC family members as well as homologues from various representative organisms. 
Stippled boxes indicate homology to the predominantly transmembrane ‘voltage-gated chloride channel’ 
motif, open boxes represent CBS domains and diagonally striped boxes represent USPA domains. 
Escherichia coli and Salmonella typhimurium ClC’s are those for which 3-dimensional crystal structures 
have been solved. 
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Fig. 2. Nucleotide dependence of ClC-1 gating. ClC-1 open probability (A) overall and separated into 
(B) common gating and (C) protopore gating components, plotted as a function of membrane potential 
with (∆) standard intracellular solution, or including 5 mM () GTP, (◊) IMP, (◆) cAMP, () AMP or 
(●) ATP . Solid lines represent fits of equation 2 to the experimental data points. D, Half-saturation 
voltages (V1/2) for common gating plotted as a function of ligand concentration for () AMP, (●) ATP, 
(◊) adenosine or (◆) adenine. Solid lines represent fits of rectangular hyperbolae to the experimental data 
points that give half-saturation concentrations of 1.2 ± 0.5 mM and 1.1 ± 0.2 mM, and maximum ∆V1/2 of 
52 ± 8 mV and 60 ± 4 mV for AMP and ATP respectively. E, Minimal open probability (Pmin) of common 
gating plotted as a function of nucleotide concentration. Symbols are the same as in panel D. Solid lines 
are straight lines connecting data points from the same data set. In all panels data points are means from 
n=4-6 cells, error bars are S.E.M.  
Fig. 3. Homology modeling of ClC-1 CBS domains. A, CBS domain sequence alignments. CBS 
domains from selected CBS-domain containing proteins are shown, including ClC-1. All proteins shown 
are human except for IMPDH, which is from Streptococcus pyogenes. ‘AMPK γ2’ represents AMP-
activated protein kinase γ2 subunit and CBS represents Cystathionine β synthase. Residue numbers are; 
CBS 1 IMPDH 95-150, ClC-1 607-662, ClC-2 582-637, ClC-Kb 549-604, ClC-5 590-645, ClC-7 613-
673, AMPK γ2 274-328 and CBS 416-469; CBS 2 IMPDH 158-211, ClC-1 819-871, ClC-2 788-840, 
ClC-Kb 626-678, ClC-5 681-733, ClC-7 723-776, AMPK γ2 355-409 and CBS 481-544. Amino acid 
sequences were aligned with ClustalW and formatted as previously described(58). Shading is as follows; 
highly conserved residues, black; conserved nonpolar residues, green; conserved uncharged polar 
residues, orange; conserved positively charged residues, blue; conserved negatively charged residues, red. 
Boxed residues indicate residues mutated in human diseases. Red letters indicate residues mutated in this 
study. B, Model of ClC-1 CBS dimer built by homology with IMPDH CBS dimer using the alignment 
shown in a). AMP, docked as described in methods section, and residues lining the putative ATP/AMP 
binding pocket are shown as sticks coloured by atom. This image was prepared using VMD version 1.8 
(33). 
 
Fig. 4. Voltage and nucleotide dependence of CBS domain mutants of ClC-1. A-F. Common gating of 
mutant ClC-1 with no nucleotide in the pipette solution (), with 5mM AMP () or with 5mM ATP () 
in the pipette solution. All abscissa are voltage in mV, with values given on panels E and F. All ordinate 
values are open probability. Mutants are A. T636A, B. P638A, C, S651A, D. H847A, E. L848A and F. 
A849V. In all panels data points are means from n = 3-6 cells, and error bars are S.E.M. Solid lines 
represent the fit of equation (2) to the experimental data points. Dashed lines and dot-dashed lines 
represent Po(V) for WT ClC-1 in the absence of nucleotide and with 5 mM ATP, respectively, in the 
pipette solution, as shown in Fig. 2A. G-H. Half-saturation voltages (V1/2) for common gating curves 
shown in panels A-F plotted against nucleotide concentration for intracellular G. AMP and H. ATP. 
Symbols are () WT ClC-1 and mutations () S651A, () T636A, (∆) P638A, (∇) L848A, () H847A 
and (●) A849V. Straight lines connect data points from the same data set. Data points are means from 
n=3-6 cells, error bars are S.E.M. 
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